Citations

Clear

904 citation(s) found for "Gordon, S".

Management of chronic neuropathic pain: a protocol for a multiple treatment comparison meta-analysis of randomised controlled trials
Mulla, Sohail, Buckley, D. Norman , Moulin, Dwight E. , Couban, Rachel , Izhar, Zain, Agarwal, Arnav , Panju, Akbar, Wang, Li , Kallyth, Sun Makosso, Turan, Alparslan , Montori, Víctor M. , Thabane, Lehana , Busse, Jason W. , Agarwal, Arnav , Sessler, Daniel I. , Guyatt, Gordon , Montori, Victor M , Thabane, Lehana

Mayo Clinic

BMJ Open | November 21, 2014 | Volume: 4 | Issue: 11 | Pages: e006112

10.1136/bmjopen-2014-006112 | PMID 25412864 Get It

Introduction Chronic neuropathic pain is associated with reduced health-related quality of life and substantial socioeconomic costs. Current research addressing management of chronic neuropathic pain is limited. No review has evaluated all interventional studies for chronic neuropathic pain, which limits attempts to make inferences regarding the relative effectiveness of treatments. Methods and analysis We will conduct a systematic review of all randomised controlled trials evaluating therapies for chronic neuropathic pain. We will identify eligible trials, in any language, by a systematic search of CINAHL, EMBASE, MEDLINE, AMED, HealthSTAR, DARE, PsychINFO and the Cochrane Central Registry of Controlled Trials. Eligible trials will be: (1) enrol patients presenting with chronic neuropathic pain, and (2) randomise patients to alternative interventions (pharmacological or non-pharmacological) or an intervention and a control arm. Pairs of reviewers will, independently and in duplicate, screen titles and abstracts of identified citations, review the full texts of potentially eligible trials and extract information from eligible trials. We will use a modified Cochrane instrument to evaluate risk of bias of eligible studies, recommendations from the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) to inform the outcomes we will collect, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to evaluate our confidence in treatment effects. When possible, we will conduct: (1) in direct comparisons, a random-effects meta-analysis to establish the effect of reported therapies on patient-important outcomes; and (2) a multiple treatment comparison meta-analysis within a Bayesian framework to assess the relative effects of treatments. We will define a priori hypotheses to explain heterogeneity between studies, and conduct meta-regression and subgroup analyses consistent with the current best practices. Ethics and Dissemination We do not require ethics approval for our proposed review. We will disseminate our findings through peer-reviewed publications and conference presentations. Trial registration number PROSPERO (CRD42014009212).
Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti–PD-1 Therapy
Joseph, Richard W. , Cappel, Mark A. , Goedjen, Brent, Gordon, Matthew C., Kirsch, Brandon, Gilstrap, Cheryl, Jambusaria‐Pahlajani, Anokhi , Cappel, Mark, Gordon, Matthew, Bagaria, Sanjay, Jambusaria-Pahlajani, Anokhi, Bagaria, Sanjay P.

Mayo Clinic

Cancer Immunology Research | October 7, 2014 | Volume: 3 | Issue: 1 | Pages: 18-22

10.1158/2326-6066.cir-14-0134 | PMID 25287118 Get It

Abstract Therapies that activate the immune system through blocking the binding of programmed death ligand 1 (PD-L1) present on tumors and PD-1 (programmed death 1) present on activated immune cells are revolutionizing the care for patients with cancer. These therapies work by inhibiting negative regulators of the immune system, thereby decreasing a tumor's ability to evade the immune system. The side effects of anti–PD-1/PD-L1 therapies are generally mild and as expected are related to autoimmune reactions. Two of the most common side effects of anti–PD-1/PD-L1 therapies are rash and pruritus occurring in approximately 20% of patients. Although the rash is generally recognized to be immune mediated, the exact mechanisms of the rash remain unclear. Herein, we report three cases of lichenoid dermatitis in three patients treated with MK-3475 (anti–PD-1) that were characterized with marked T-cell infiltrates with few PD-1–positive cells. The rashes in all three patients were relatively mild, allowing treatment to continue despite the rashes. Cancer Immunol Res; 3(1); 18–22. ©2014 AACR.
XIX. Blastomycosis of the Larynx
New, Gordon B.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | October 3, 2014 | Volume: 37 | Issue: 1 | Pages: 240-250

10.1177/000348942803700119 Get It

IX. Treatment of Fibromas of the Nasopharynx: Report of Thirty-Two Cases
New, Gordon B., Figi, Fred A.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | October 3, 2014 | Volume: 34 | Issue: 1 | Pages: 191-196

10.1177/000348942503400109 Get It

XXXIII. Treatment of Multiple Papillomas of the Larynx in Children
New, Gordon B.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | October 3, 2014 | Volume: 30 | Issue: 3 | Pages: 631-641

10.1177/000348942103000301 Get It

Abstract 4138: Five prognostic subgroups differ in expression of Akt pathway genes: Biomarkers for therapy selection
Joy, Anna , Ramesh, Archana , Bachoo, Robert , Shapiro, William, Smirnov, Ivan V. , Kim, Seungchan , Sarkaria, Jann N. , Ram, Prahlad T. , Mills, Gordon B. , Feuerstein, Burt G.

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 71 | Issue: 8_Supplement | Pages: 4138-4138

10.1158/1538-7445.am2011-4138 Get It

Abstract Biomarkers that select patients for therapeutics would benefit clinical trial design and patient care. The Akt pathway is a therapeutic target in Glioblastoma Multiforme (GBM) and an important determinant of patient outcome. However, it is not known whether activity of this pathway varies among GBM tumors. To investigate we used Akt pathway genes from published GBM expression datasets. We detected 5 patterns of Akt pathway gene expression and these Akt subgroups correlated with prognosis. We analyzed networks within subgroups using both gene set enrichment analysis and a novel method that scores relevance based on both expression and local network connectivity (Komurov et al., PLoS Comput Biol. 2010 6:8, 1-10). The results suggest therapeutic targets within the individual subgroups. Furthermore, preliminary analysis indicates that human GBM xenograft models and primary human GBM manifest similar Akt subgroups. We are investigating rodent xenograft models of Akt subgroups to evaluate subgroup-specific drug sensitivity, and will present a method and examples of analysis integrating gene expression data from human GBM xenografts and primary human GBM. We hypothesize that Akt subgroups will help personalize treatment for GBM therapeutics. Supported by Barrow Neurological Foundation, Halle Family Foundation, and NIH 1 K01 NS064952-01A1 (AMJ). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4138. doi:10.1158/1538-7445.AM2011-4138
Abstract B37: Proteomic and metabolomic analyses of glioblastoma using mass spectrometry.
Ha, Soo Jung, Showalter, Gordon, Cai, Shanbao , Wang, Haiyan , Liu, Wei Michael, Springer, John, Pollok, Karen E. , Rickus, Jenna L. , Sarkaria, Jann N. , Adamec, Jiří , Clase, Kari Lynn

Mayo Clinic

Molecular Cancer Therapeutics | August 14, 2014 | Volume: 12 | Issue: 11_Supplement | Pages: B37-B37

10.1158/1535-7163.targ-13-b37 Get It

Abstract Glioblastoma (GBM) is the most common and malignant form of primary brain tumor. Average survival rate of GBM is 12-15 months from diagnosis. Due to its highly invasive nature, current treatment options have not been able to improve the survival rate in past 20 years. In order to discover GBM therapeutic targets, omics technologies have been widely used in order to identify potential biomarkers. Identification of cancer biomarkers for diagnosis and prognosis continues to evolve as clinical specimen pipelines and technologies are optimized. This research study focused on investigating proteins, metabolites and lipids biomarkers and patterns of human GBM xenografts employing mass spectrometry. Human tumor cell lines GBM 10 and GBM 43 were injected in the right cerebral hemisphere and flank sites in NOD/SCID mice (n = 10 mice per group). After harvesting brain and flank tumors and control brain from mouse models, protein, metabolites, and lipids of tumor samples were collected through one simple extraction procedure, which may solve sample preparation difficulties in omics studies, developed by Dr. Jiri Adamec. These samples were analyzed by reverse phase high performance liquid chromatography - Fourier transform ion cyclotron resonance mass spectrometry (LC-FTMS). FTMS analyzers have the highest resolving power of all MS instruments, which is ideal for complex mixtures such as GBM tissue. Spectra obtained from the FTMS analysis were analyzed using Student t-tests to detect significant differences in tissue profiles at a level of p = 0.05. Compounds below this threshold were identified through a database using the m/z ratio. Lipidomic analysis indicated the possible up and down-regulation of several lipids classes in GBM tissue connected to metabolic pathways, tumor proliferation and immunodepression, such as glycerophospholipids, both up- and down-regulated (e.g. PC38:4 or PG 35:2, respectively), and down-regulated glycosphingolipids (Galβ1-3GlcNAcβ1-3Galβ1-4Glc-Cer, Galβ1-4GlcNAcβ1-3Galβ1-4Glc-Cer), and triglycerides (TG 55:9, 53:4,52:8). We expect that integrated studies of proteomics, metabolomics, and lipidomics increase the confidence of identification of potential biomarkers. Accompanying these studies is a collaborative effort to improve the effectiveness and efficiency of computational pipelines that are imperative to the analytics, visualization, identification, and interpretation of the omics data. Only by carefully integrating the computational pipelines can we successfully perform the types of integrative studies needed to advance the identification of cancer biomarkers for diagnosis and prognosis, and our integrative studies serve as a case study for our pipeline advancement efforts. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B37. Citation Format: Soo Jung Ha, Gordon Showalter, Jenna Rickus, Shanbao Cai, Haiyan Wang, Wei Michael Liu, Jann N. Sarkaria, John Springer, Jiri Adamec, Karen E. Pollok, Kari L. Clase. Proteomic and metabolomic analyses of glioblastoma using mass spectrometry. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B37.